Trials / Completed
CompletedNCT00081926
Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 112 (planned)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the molecular response to high dose Gleevec in newly diagnosed patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase. This study will evaluate the ability of Gleevec to reduce the amount of abnormal protein that occurs in patients with CML. Patients who are eligible to participate will be treated for 18 months. This trial will include male or female patients 18 years or older who are newly diagnosed (within 6 months) with CML.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gleevec |
Timeline
- Start date
- 2003-10-01
- Completion
- 2007-03-01
- First posted
- 2004-04-29
- Last updated
- 2009-11-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00081926. Inclusion in this directory is not an endorsement.